Salt Creek Medical Device Development

Salt Creek targets companies at the prototype or pre-FDA submission stage, typically seed and Series A rounds. The firm's model requires operational involvement during design verification, clinical trials, and regulatory submission — stages where most venture investors consider the technical risk too high and the timeline too long. Investments are almost exclusively pre-revenue, with capital structured to fund the company through initial FDA clearance.

The firm sources primarily through the Southern California medtech ecosystem, leveraging relationships with university technology transfer offices, medtech incubators, and a network of operating partners who are former executives at established device companies. This network provides early visibility into spinout opportunities and clinician-founded startups, particularly in the Orange County and San Diego corridors.

The firm focuses on Class II and III medical devices — categories that require FDA 510(k) or PMA clearance — where regulatory complexity creates a barrier to entry that Salt Creek's in-house expertise can address. Specific device categories are not publicly enumerated, but the firm's location and operating-partner network suggest emphasis on cardiovascular, orthopedic, and surgical device subsectors common to Southern California's medtech cluster.

The firm is structured as a private equity/venture capital firm, not a single-family office. It raises capital from external limited partners and deploys it through standard fund structures. The operational intensity of its portfolio engagement — embedding regulatory and quality-systems experts inside portfolio companies — distinguishes it from typical healthcare VC funds.

Given the regulatory timelines for medical devices, Salt Creek's holding period typically spans five to seven years from initial investment to exit. The firm targets trade-sale exits to strategic acquirers — large medtech companies that acquire cleared devices to fill pipeline gaps — rather than IPOs, aligning with the consolidation dynamics of the device industry.